Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project.

In April 2022, Iktos announced a strategic collaboration agreement Teijin Pharma.

Under the agreement, Iktos' generative modelling technology will be implemented and applied to several Teijin Pharma’s small molecule drug discovery projects to expedite the identification of potential pre-clinical candidates.

Iktos and Teijin will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process, leveraging Iktos’ proprietary know-how in AI for computer-aided drug design and complementing Teijin’s research and development capabilities. No financial terms of the deal were disclosed.

Prior to this deal, Iktos has entered into a collaboration with Japan’s Ono Pharmaceutical and with South Korean biotech Astrogen to try to discover new small molecules for Parkinson's disease.